Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Perphenazine
Drug ID BADD_D01743
Description An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
Indications and Usage For use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.
Marketing Status Prescription; Discontinued
ATC Code N05AB03
DrugBank ID DB00850
KEGG ID D00503
MeSH ID D010546
PubChem ID 4748
TTD Drug ID D02HED
NDC Product Code 70518-3033; 70518-0940; 52536-164; 70518-1125; 0591-4103; 0591-4102; 0781-8046; 0591-4104; 63629-2251; 70518-0710; 0781-8047; 0603-5062; 68084-602; 63629-2250; 52536-168; 0781-8048; 68382-594; 70518-2639; 0603-5060; 70518-2985; 0904-6600; 64980-293; 65372-1191; 70771-1043; 68084-607; 52536-170; 70518-3018; 0603-5061; 70518-2890; 0904-6601; 63629-2248; 0591-4101; 64980-292; 70518-0458; 0603-5063; 70518-0731; 63629-2253; 70771-1044; 68382-592; 70518-3108; 70518-3106; 70518-1109; 70771-1041; 63629-2252; 70518-3257; 64980-290; 70518-1739; 68382-591; 63629-2249; 46204-0003; 70518-3121; 63629-7252; 52536-162; 68382-593; 53808-1124; 0781-8049; 42973-165; 64980-291; 70518-1133; 70771-1042; 0904-6599
Synonyms Perphenazine | Perfenazine | Chlorpiprazine | Trilafon
Chemical Information
Molecular Formula C21H26ClN3OS
CAS Registry Number 58-39-9
SMILES C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Incontinence20.02.02.004; 17.05.01.006; 07.01.06.011--Not Available
Infection11.01.08.002--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Jaundice cholestatic09.01.01.005--Not Available
Keratopathy06.06.03.007--Not Available
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.003--
Lenticular opacities06.06.01.003--Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Leukopenia01.02.02.001--Not Available
Loss of consciousness17.02.04.004--Not Available
Menstrual disorder21.01.01.004--Not Available
Miosis06.05.03.003; 17.02.11.002--Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Mydriasis17.02.11.003; 06.05.03.004--Not Available
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Neurogenic bladder20.03.03.001; 17.10.01.002--Not Available
Neuroleptic malignant syndrome17.05.02.003; 12.03.01.003; 15.05.04.015; 08.05.01.005--Not Available
Oculogyric crisis17.01.03.002; 06.05.02.002--Not Available
Oedema peripheral02.05.04.007; 14.05.06.011; 08.01.07.007--
Opisthotonus17.01.03.005--Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Pallor08.01.03.032; 24.03.04.001; 23.03.03.031--Not Available
Pancytopenia01.03.03.003--Not Available
Parkinsonism17.01.05.003--Not Available
Parotid gland enlargement07.06.03.001--Not Available
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages